Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Michigan Cornea Consultants, PC.
Recruitment status was  Recruiting
Kresge Eye Institute
Information provided by:
Michigan Cornea Consultants, PC Identifier:
First received: July 7, 2011
Last updated: July 11, 2012
Last verified: July 2011

Severe dry eye is a debilitating ocular disease resulting in loss of vision, reduced day-to-day function and significant discomfort. Tear substitutes are an important part of the treatment of all patients, however, even with aggressive us, the corneal(ocular)surface often remains very irregular due to poor surface healing.

The agent being evaluated in this study, Thymosin Beta 4, promotes healing of the corneal surface and has been studied in patients with recalcitrant corneal ulcers and erosions with significant success (Arch Ophthalmol. 2010;128(5):636-638., Ann of the NY Acad of Sci, May, 2010).

The study hypothesis is that Thymosin Beta 4, in its role as a modulator of corneal surface healing, may be able to promote healing of the corneal surface allowing for more conventional modalities to take over and maintain a smooth and regular ocular surface. The investigators hope to be able to demonstrate an improvement in visual acuity, surface healing and a reduction in dry-eye related symptoms.

Condition Intervention Phase
Dry Eye
Sjogren's Syndrome
Graft vs. Host Disease
Drug: Thymosin Beta 4 eye drops vs. vehicle
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye

Resource links provided by NLM:

Further study details as provided by Michigan Cornea Consultants, PC:

Primary Outcome Measures:
  • Corneal and Conjunctival Staining - Change from baseline [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    The corneal and conjunctival surface will be monitored during treatment and for a 30 day period afterwards for improvement of surface staining (using a standardized grading system) and corresponding visual acuity (Snellen) and symptomatic improvement using the validated Ocular Surface Disease Index (OSDI).

Secondary Outcome Measures:
  • Snellen visual acuity - Change from baseline [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Snellen visual acuity will be measured using standardized eye charts and lighting conditions.

Estimated Enrollment: 20
Study Start Date: March 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Thymosin Beta 4 eye drops vs. vehicle
    Patients will be randomized and will receive either Thymosin Beta 4 eye drops or the same eye drops without the Thymosin Beta 4.
Detailed Description:

See above


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Schirmers of < 5 mm at 5 minutes
  • TFBUT: less than 10 seconds
  • Corneal staining of >3 of 15: conjunctival staining of >3 of 18
  • Ocular Surface Disease Index of > 50
  • Presumed best corrected vision of 20/60 or better

Exclusion Criteria:

  • Acute or inflammatory corneal disease
  • Pregnancy or lactation
  • Monocular status
  • Punctal occlusion within 30 days
  • Ocular surgery within 3 months
  • Corneal thinning of >50%
  • Active corneal infection
  • History of ocular malignancy
  • Retinal neovascularization
  • Current use of topical cyclosporin A
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01393132

Contact: Tina Macleod 248-350-1130
Contact: Steven P Dunn 248-350-1130

United States, Michigan
Michigan Cornea Consultants, P.C. Recruiting
Southfield, Michigan, United States, 48034
Contact: Tina Macleod    248-350-1130   
Contact: Steven P Dunn, MD    248-350-1130   
Principal Investigator: Steven P Dunn, MD         
Sub-Investigator: David G. Heidemann, MD         
Sub-Investigator: Christopher YC Chow, MD         
Sub-Investigator: Gabriel Sosne, MD         
Sponsors and Collaborators
Michigan Cornea Consultants, PC
Kresge Eye Institute
Principal Investigator: Steven P Dunn, M.D. Michigan Cornea Consultants, P.C.
  More Information

No publications provided

Responsible Party: Steven P. Dunn, M.D., Michigan Cornea Consultants, P.C. Identifier: NCT01393132     History of Changes
Other Study ID Numbers: 1003008179
Study First Received: July 7, 2011
Last Updated: July 11, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Michigan Cornea Consultants, PC:
Dry Eye
Sjogren's Syndrome
Graft vs. Host Disease
Rheumatoid arthritis
Systemic lupus erythematosus

Additional relevant MeSH terms:
Sjogren's Syndrome
Graft vs Host Disease
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Dry Eye Syndromes
Eye Diseases
Immune System Diseases
Joint Diseases
Lacrimal Apparatus Diseases
Mouth Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salivary Gland Diseases
Stomatognathic Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Pharmacologic Actions
Therapeutic Uses processed this record on March 31, 2015